---

---

# Selected readings

### 2020

Mulinari, S, Davis, C, Ozieranski, P. "Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe". J. White Collar Corp. Crime 2020:2631309X2097047. [SagePub&nbsp;![External link](/img/ext-link.svg#line-height)](http://journals.sagepub.com/doi/10.1177/2631309X20970477) 

Ozieranski, P, Csanádi, M, Rickard, E, Mulinari, S. "Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)". BMJ Open 2020; 10(9):e037351. [BMJ&nbsp;![External link](/img/ext-link.svg#line-height)](https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-037351)

Mulinari, S, Vilhelmsson, A, Rickard, E, Ozieranski, P. "Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs". PLoS One 2020; 15(6):e0235021. [PLoS&nbsp;![External link](/img/ext-link.svg#line-height)](https://dx.plos.org/10.1371/journal.pone.0235021)

### 2019

Cohen, D, Mulinari, S, Ozieranski, P. "The whistleblowing drama behind Astellas's suspension from the ABPI". BMJ 2019:l4353. [BMJ&nbsp;![External link](/img/ext-link.svg#line-height)](https://www.bmj.com/lookup/doi/10.1136/bmj.l4353)

Ozieranski, P, Csanadi, M, Rickard, E, Tchilingirian, J, Mulinari, S. "Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015". JAMA Netw. Open 2019; 2(6):e196253. [JAMA&nbsp;![External link](/img/ext-link.svg#line-height)](http://jamanetworkopen.jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2019.6253)

Ozieranski, P, Rickard, E, Mulinari, S. "Exposing drug industry funding of UK patient organisations". BMJ 2019:l1806. [BMJ&nbsp;![External link](/img/ext-link.svg#line-height)](https://www.bmj.com/lookup/doi/10.1136/bmj.l1806)

Rickard, E, Ozieranski, P, Mulinari, S. "Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK". Health Policy (New. York). 2019; 123(12):1244–1250. [Elsevier&nbsp;![External link](/img/ext-link.svg#line-height)](https://linkinghub.elsevier.com/retrieve/pii/S0168851019301915)

### 2018

Fabbri, A, Santos, A, Mezinska, S, Mulinari, S, Mintzes, B. "Sunshine policies and murky shadows in Europe: Disclosure of pharmaceutical industry payments to health professionals in nine European countries". Int. J. Heal. Policy Manag. 2018. [IJHPM&nbsp;![External link](/img/ext-link.svg#line-height)](https://doi.org/10.15171/ijhpm.2018.20)

Mulinari, S, Ozieranski, P. "Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: Analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts". BMJ Open 2018. [BMJ&nbsp;![External link](/img/ext-link.svg#line-height)](https://doi.org/10.1136/bmjopen-2018-023094)

### 2016

Dunn, A, Coiera, E, Mandl, K, Bourgeois, F. "Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency". Res. Integr. Peer Rev. 2016. [RIPR&nbsp;![External link](/img/ext-link.svg#line-height)](https://doi.org/10.1186/s41073-016-0006-7)